company background image
INDSWFTLAB logo

Ind-Swift Laboratories NSEI:INDSWFTLAB Stock Report

Last Price

₹100.15

Market Cap

₹5.9b

7D

-3.1%

1Y

81.3%

Updated

28 Mar, 2024

Data

Company Financials

Ind-Swift Laboratories Limited

NSEI:INDSWFTLAB Stock Report

Market Cap: ₹5.9b

INDSWFTLAB Stock Overview

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India.

INDSWFTLAB fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health4/6
Dividends0/6

Ind-Swift Laboratories Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ind-Swift Laboratories
Historical stock prices
Current Share Price₹100.15
52 Week High₹123.40
52 Week Low₹55.10
Beta0.14
1 Month Change-9.57%
3 Month Change-3.28%
1 Year Change81.27%
3 Year Change33.71%
5 Year Change159.46%
Change since IPO457.94%

Recent News & Updates

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Dec 28
Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Recent updates

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Dec 28
Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Jul 22
These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Jul 12
Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Feb 17
Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

Dec 30
We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Nov 11
These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Jun 27
Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Shareholder Returns

INDSWFTLABIN PharmaceuticalsIN Market
7D-3.1%2.4%1.8%
1Y81.3%65.8%48.6%

Return vs Industry: INDSWFTLAB exceeded the Indian Pharmaceuticals industry which returned 63.9% over the past year.

Return vs Market: INDSWFTLAB exceeded the Indian Market which returned 47.3% over the past year.

Price Volatility

Is INDSWFTLAB's price volatile compared to industry and market?
INDSWFTLAB volatility
INDSWFTLAB Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.6%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.0%

Stable Share Price: INDSWFTLAB has not had significant price volatility in the past 3 months.

Volatility Over Time: INDSWFTLAB's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19951,496n/ahttps://www.indswiftlabs.com

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services.

Ind-Swift Laboratories Limited Fundamentals Summary

How do Ind-Swift Laboratories's earnings and revenue compare to its market cap?
INDSWFTLAB fundamental statistics
Market cap₹5.92b
Earnings (TTM)₹431.95m
Revenue (TTM)₹12.00b

13.7x

P/E Ratio

0.5x

P/S Ratio

Is INDSWFTLAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INDSWFTLAB income statement (TTM)
Revenue₹12.00b
Cost of Revenue₹6.25b
Gross Profit₹5.76b
Other Expenses₹5.33b
Earnings₹431.95m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)7.31
Gross Margin47.97%
Net Profit Margin3.60%
Debt/Equity Ratio109.8%

How did INDSWFTLAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.